Comparative Pharmacology
Head-to-head clinical analysis: K LEASE versus KLOTRIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K LEASE versus KLOTRIX.
K-LEASE vs KLOTRIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement therapy; increases extracellular potassium levels to correct hypokalemia.
KLOTRIX is a combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. The ARB component blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. The thiazide diuretic increases sodium and water excretion by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule of the kidney.
1 tablet (25 mEq) orally 2-4 times daily with meals; maximum 100 mEq/day.
Adults: 500-1000 mg orally every 6 hours; maximum 4000 mg/day.
None Documented
None Documented
Not applicable; exogenous potassium is not subject to terminal elimination half-life as it is rapidly redistributed and excreted. Clinical context: the half-life of redistribution is minutes to hours.
Terminal half-life 12 hours; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min)
Excreted renally as potassium chloride; elimination is 100% renal. No biliary or fecal excretion.
Renal 70% as unchanged drug, fecal 30% via biliary secretion
Category C
Category C
Potassium Supplement
Potassium Supplement